Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 3.2%

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) were up 3.2% during mid-day trading on Friday . The company traded as high as $7.28 and last traded at $7.05. Approximately 257,998 shares changed hands during trading, an increase of 166% from the average daily volume of 96,991 shares. The stock had previously closed at $6.83.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Nuvectis Pharma in a research note on Wednesday, May 8th.

Nuvectis Pharma Price Performance

The firm has a 50 day moving average price of $6.61 and a 200 day moving average price of $7.76.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, May 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.15. On average, research analysts expect that Nuvectis Pharma, Inc. will post -1.29 EPS for the current fiscal year.

Institutional Trading of Nuvectis Pharma

Several institutional investors and hedge funds have recently modified their holdings of NVCT. Vanguard Group Inc. increased its stake in Nuvectis Pharma by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock worth $2,450,000 after buying an additional 4,517 shares in the last quarter. Blue Zone Wealth Advisors LLC purchased a new stake in Nuvectis Pharma in the 1st quarter worth $118,000. Edmond DE Rothschild Holding S.A. bought a new position in shares of Nuvectis Pharma during the 4th quarter valued at about $160,000. Strs Ohio grew its position in shares of Nuvectis Pharma by 59.0% during the fourth quarter. Strs Ohio now owns 6,200 shares of the company’s stock valued at $51,000 after purchasing an additional 2,300 shares in the last quarter. Finally, Baldwin Brothers LLC MA increased its holdings in shares of Nuvectis Pharma by 22.0% in the fourth quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock worth $1,185,000 after purchasing an additional 25,660 shares during the last quarter. 96.77% of the stock is currently owned by institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.